ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO054

Serum Cystatin C on Admission: A Potential Predictor for Hospital-Acquired AKI in Patients with an Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology, Risk Factors, and Prevention

Author

  • Chen, Dawei, Nanjing First Hospital, Nanging, JIangsu, China
Background

Hospital-acquired acute kidney injury (HA-AKI) was associated with poor prognosis. In this study, we performed to determine whether serum Cystatin C on admission could predict AKI in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD).

Methods

This study was conducted from January 2014 to January 2017, and data from adult inpatients with AECOPD were analyzed retrospectively. A total of 1035 patients were included, 79 patients were identified with HA-AKI. Univariate and multivariate logistic regression analyses were used for investigating the predictors for HA-AKI in patients with AECOPD.

Results

Prevalence of HA-AKI was 7.6%. HA-AKI was also associated with poor prognosis, and was an independent risk factor for inpatient mortality for patients with AECOPD. Compared with patients without AKI, age, and the level of urea, Cystatin C, and platelet count on admission were four independent factors for HA-AKI in patients with AECOPD. Cystatin C (OR, 5.22; 95% CI, 2.49-10.95; P < 0.001) was the independent and significant predictor for AKI in patients with AECOPD. HA-AKI in patients with AECOPD could be identified with a sensitivity of 73.5% at specificity of 75.9% (AUC = 0.803, 95% CI 0.747 - 0.859) by Cystatin C (cut-off value = 1.3 mg/L). In addition, HA-AKI in patients with AECOPD could be identified with a sensitivity of 75.9% at specificity of 82.0% (AUC = 0.853, 95% CI 0.810 - 0.896) by the model.

Conclusion

Serum Cystatin C on admission may be adopted to predict the potential risk of HA-AKI in patients with AECOPD.